These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

239 related articles for article (PubMed ID: 25313354)

  • 1. Inhibition of Nek2 by small molecules affects proteasome activity.
    Meng L; Carpenter K; Mollard A; Vankayalapati H; Warner SL; Sharma S; Tricot G; Zhan F; Bearss DJ
    Biomed Res Int; 2014; 2014():273180. PubMed ID: 25313354
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Bortezomib induces G2-M arrest in human colon cancer cells through ROS-inducible phosphorylation of ATM-CHK1.
    Hong YS; Hong SW; Kim SM; Jin DH; Shin JS; Yoon DH; Kim KP; Lee JL; Heo DS; Lee JS; Kim TW
    Int J Oncol; 2012 Jul; 41(1):76-82. PubMed ID: 22552540
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Proteasome inhibitor bortezomib overcomes P-gp-mediated multidrug resistance in resistant leukemic cell lines.
    Zheng B; Zhou R; Gong Y; Yang X; Shan Q
    Int J Lab Hematol; 2012 Jun; 34(3):237-47. PubMed ID: 22145750
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effect of noncompetitive proteasome inhibition on bortezomib resistance.
    Li X; Wood TE; Sprangers R; Jansen G; Franke NE; Mao X; Wang X; Zhang Y; Verbrugge SE; Adomat H; Li ZH; Trudel S; Chen C; Religa TL; Jamal N; Messner H; Cloos J; Rose DR; Navon A; Guns E; Batey RA; Kay LE; Schimmer AD
    J Natl Cancer Inst; 2010 Jul; 102(14):1069-82. PubMed ID: 20505154
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Bortezomib potentially inhibits cellular growth of vascular endothelial cells through suppression of G2/M transition.
    Tamura D; Arao T; Tanaka K; Kaneda H; Matsumoto K; Kudo K; Aomatsu K; Fujita Y; Watanabe T; Saijo N; Kotani Y; Nishimura Y; Nishio K
    Cancer Sci; 2010 Jun; 101(6):1403-8. PubMed ID: 20367638
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Interferon-γ-induced upregulation of immunoproteasome subunit assembly overcomes bortezomib resistance in human hematological cell lines.
    Niewerth D; Kaspers GJ; Assaraf YG; van Meerloo J; Kirk CJ; Anderl J; Blank JL; van de Ven PM; Zweegman S; Jansen G; Cloos J
    J Hematol Oncol; 2014 Jan; 7():7. PubMed ID: 24418325
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Proteasome-based mechanisms of intrinsic and acquired bortezomib resistance in non-small cell lung cancer.
    de Wilt LH; Jansen G; Assaraf YG; van Meerloo J; Cloos J; Schimmer AD; Chan ET; Kirk CJ; Peters GJ; Kruyt FA
    Biochem Pharmacol; 2012 Jan; 83(2):207-17. PubMed ID: 22027222
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Destabilizing NEK2 overcomes resistance to proteasome inhibition in multiple myeloma.
    Franqui-Machin R; Hao M; Bai H; Gu Z; Zhan X; Habelhah H; Jethava Y; Qiu L; Frech I; Tricot G; Zhan F
    J Clin Invest; 2018 Jul; 128(7):2877-2893. PubMed ID: 29863498
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Sensitizing human multiple myeloma cells to the proteasome inhibitor bortezomib by novel curcumin analogs.
    Mujtaba T; Kanwar J; Wan SB; Chan TH; Dou QP
    Int J Mol Med; 2012 Jan; 29(1):102-6. PubMed ID: 22012631
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Discovery of Peptide Boronate Derivatives as Histone Deacetylase and Proteasome Dual Inhibitors for Overcoming Bortezomib Resistance of Multiple Myeloma.
    Zhou Y; Liu X; Xue J; Liu L; Liang T; Li W; Yang X; Hou X; Fang H
    J Med Chem; 2020 May; 63(9):4701-4715. PubMed ID: 32267687
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Therapeutic melting pot of never in mitosis gene a related kinase 2 (Nek2): a perspective on Nek2 as an oncology target and recent advancements in Nek2 small molecule inhibition.
    Frett B; Brown RV; Ma M; Hu W; Han H; Li HY
    J Med Chem; 2014 Jul; 57(14):5835-44. PubMed ID: 24517277
    [TBL] [Abstract][Full Text] [Related]  

  • 12. RNAi screen of the druggable genome identifies modulators of proteasome inhibitor sensitivity in myeloma including CDK5.
    Zhu YX; Tiedemann R; Shi CX; Yin H; Schmidt JE; Bruins LA; Keats JJ; Braggio E; Sereduk C; Mousses S; Stewart AK
    Blood; 2011 Apr; 117(14):3847-57. PubMed ID: 21289309
    [TBL] [Abstract][Full Text] [Related]  

  • 13. TM-233, a novel analog of 1'-acetoxychavicol acetate, induces cell death in myeloma cells by inhibiting both JAK/STAT and proteasome activities.
    Sagawa M; Tabayashi T; Kimura Y; Tomikawa T; Nemoto-Anan T; Watanabe R; Tokuhira M; Ri M; Hashimoto Y; Iida S; Kizaki M
    Cancer Sci; 2015 Apr; 106(4):438-46. PubMed ID: 25613668
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Overexpression of NIMA related kinase 2 in multiple myeloma and its relevance with disease features and prognosis to bortezomib treatment.
    Gu X; Wang Z; Pan Q
    J Clin Pharm Ther; 2022 Oct; 47(10):1690-1697. PubMed ID: 36087032
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Dynamic recruitment of Nek2 kinase to the centrosome involves microtubules, PCM-1, and localized proteasomal degradation.
    Hames RS; Crookes RE; Straatman KR; Merdes A; Hayes MJ; Faragher AJ; Fry AM
    Mol Biol Cell; 2005 Apr; 16(4):1711-24. PubMed ID: 15659651
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Identification by high-throughput screening of viridin analogs as biochemical and cell-based inhibitors of the cell cycle-regulated nek2 kinase.
    Hayward DG; Newbatt Y; Pickard L; Byrne E; Mao G; Burns S; Sahota NK; Workman P; Collins I; Aherne W; Fry AM
    J Biomol Screen; 2010 Sep; 15(8):918-927. PubMed ID: 20664067
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Bortezomib and fenretinide induce synergistic cytotoxicity in mantle cell lymphoma through apoptosis, cell-cycle dysregulation, and IκBα kinase downregulation.
    Cowan AJ; Frayo SL; Press OW; Palanca-Wessels MC; Pagel JM; Green DJ; Gopal AK
    Anticancer Drugs; 2015 Oct; 26(9):974-83. PubMed ID: 26237500
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Noncompetitive modulation of the proteasome by imidazoline scaffolds overcomes bortezomib resistance and delays MM tumor growth in vivo.
    Lansdell TA; Hurchla MA; Xiang J; Hovde S; Weilbaecher KN; Henry RW; Tepe JJ
    ACS Chem Biol; 2013 Mar; 8(3):578-87. PubMed ID: 23198928
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Proteasome inhibition with bortezomib induces cell death in GBM stem-like cells and temozolomide-resistant glioma cell lines, but stimulates GBM stem-like cells' VEGF production and angiogenesis.
    Bota DA; Alexandru D; Keir ST; Bigner D; Vredenburgh J; Friedman HS
    J Neurosurg; 2013 Dec; 119(6):1415-23. PubMed ID: 24093630
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Molecular basis of differential sensitivity of myeloma cells to clinically relevant bolus treatment with bortezomib.
    Shabaneh TB; Downey SL; Goddard AL; Screen M; Lucas MM; Eastman A; Kisselev AF
    PLoS One; 2013; 8(2):e56132. PubMed ID: 23460792
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.